LDL

  • All (6)
  • LDL Inhibitor (1)
  • LDL Modulators (5)
  • New LDL Products
Cat.No. Product Name Information Product Use Citations Product Validations
S1655 Ezetimibe (SCH-58235) Ezetimibe (SCH-58235) is a potent, selective, cholesterol absorption inhibitor that is used to lower cholesterol.
J Med Chem, 2025, 68(2):1179-1194
Toxicol Lett, 2025, 406:31-37
J Immunother Cancer, 2024, 12(11)e009805
Verified customer review of Ezetimibe (SCH-58235)
S2119 Probucol Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
J Immunother Cancer, 2024, 12(11)e009805
Int Immunopharmacol, 2023, 116:109820
E3811 Cashew Extract Cashew Extract is extracted from Anacardium occidentale, which lowers the levels of LDL cholesterol and may help to prevent heart disease due to its high magnesium content.
S9187 Phillygenin Phillygenin (Sylvatesmin), a bioactive intergradient in Osmanthus fragrans, has anti-inflammatory, anti-obesity and antipyretic activities. It could reduce blood lipid levels and low density lipoprotein.
S2748 Anacetrapib (MK-0859) Anacetrapib (MK-0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM. It increases HDL-C and decreases LDL-C, and does not increase aldosterone or blood pressure. This compound is in Phase 3.
Circulation, 2021, 143(9):921-934
J Phys Chem B, 2016, 120(33):8254-63
Atherosclerosis, 2014, 235(2):449-62
S7953 Bempedoic acid (ETC-1002) Bempedoic acid (ETC-1002) is an orally available, once-daily LDL-C lowering small molecule designed to reduce elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. This compound is an activator of hepatic AMP-activated protein kinase (AMPK) and has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).
Cancer Cell, 2025, 43(4):776-796.e14
iScience, 2023, 26(12):108532
Oncol Rep, 2023, 49(2)32
E3811 Cashew Extract Cashew Extract is extracted from Anacardium occidentale, which lowers the levels of LDL cholesterol and may help to prevent heart disease due to its high magnesium content.
S1655 Ezetimibe (SCH-58235) Ezetimibe (SCH-58235) is a potent, selective, cholesterol absorption inhibitor that is used to lower cholesterol.
J Med Chem, 2025, 68(2):1179-1194
Toxicol Lett, 2025, 406:31-37
J Immunother Cancer, 2024, 12(11)e009805
Verified customer review of Ezetimibe (SCH-58235)
S2119 Probucol Probucol (DH-581) is an anti-hyperlipidemic drug by lowering the level of cholesterol in the bloodstream by increasing the rate of LDL catabolism.
J Immunother Cancer, 2024, 12(11)e009805
Int Immunopharmacol, 2023, 116:109820
S9187 Phillygenin Phillygenin (Sylvatesmin), a bioactive intergradient in Osmanthus fragrans, has anti-inflammatory, anti-obesity and antipyretic activities. It could reduce blood lipid levels and low density lipoprotein.
S2748 Anacetrapib (MK-0859) Anacetrapib (MK-0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM. It increases HDL-C and decreases LDL-C, and does not increase aldosterone or blood pressure. This compound is in Phase 3.
Circulation, 2021, 143(9):921-934
J Phys Chem B, 2016, 120(33):8254-63
Atherosclerosis, 2014, 235(2):449-62
S7953 Bempedoic acid (ETC-1002) Bempedoic acid (ETC-1002) is an orally available, once-daily LDL-C lowering small molecule designed to reduce elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. This compound is an activator of hepatic AMP-activated protein kinase (AMPK) and has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).
Cancer Cell, 2025, 43(4):776-796.e14
iScience, 2023, 26(12):108532
Oncol Rep, 2023, 49(2)32